<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Clin Proteomics</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Proteomics</journal-id>
<journal-title-group>
<journal-title>Clinical Proteomics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1542-6416</issn>
<issn pub-type="epub">1559-0275</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31341447</article-id>
<article-id pub-id-type="pmc">6631513</article-id>
<article-id pub-id-type="publisher-id">9252</article-id>
<article-id pub-id-type="doi">10.1186/s12014-019-9252-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Lipid metabolism impairment in patients with sepsis secondary to hospital acquired pneumonia, a proteomic analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Sharma</surname>
<given-names>Narendra Kumar</given-names>
</name>
<address>
<email>drnarendraks@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Ferreira</surname>
<given-names>Bianca Lima</given-names>
</name>
<address>
<email>bianca.rodrigueslima@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tashima</surname>
<given-names>Alexandre Keiji</given-names>
</name>
<address>
<email>tashima.ak@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brunialti</surname>
<given-names>Milena Karina Colo</given-names>
</name>
<address>
<email>milena.brunialti@unifesp.br</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Torquato</surname>
<given-names>Ricardo Jose Soares</given-names>
</name>
<address>
<email>torquato.bioq@epm.br</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bafi</surname>
<given-names>Antonio</given-names>
</name>
<address>
<email>tonybafi@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Assuncao</surname>
<given-names>Murillo</given-names>
</name>
<address>
<email>murilloassuncao@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Azevedo</surname>
<given-names>Luciano Cesar Pontes</given-names>
</name>
<address>
<email>luciano.azevedo@hsl.org.br</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1149-4598</contrib-id>
<name>
<surname>Salomao</surname>
<given-names>Reinaldo</given-names>
</name>
<address>
<email>rsalomao@unifesp.br</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0514 7202</institution-id><institution-id institution-id-type="GRID">grid.411249.b</institution-id><institution>Division of Infectious Diseases, </institution><institution>Escola Paulista de Medicina, Universidade Federal de São Paulo, </institution></institution-wrap>Rua Pedro de Toledo, 669, 10th Floor, Sao Paulo, SP 04039-032 Brazil </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0514 7202</institution-id><institution-id institution-id-type="GRID">grid.411249.b</institution-id><institution>Department of Biochemistry, </institution><institution>Escola Paulista de Medicina, Universidade Federal de São Paulo, </institution></institution-wrap>São Paulo, SP 04023-900 Brazil </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.413463.7</institution-id><institution>Intensive Care Unit, </institution><institution>Hospital São Paulo, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, </institution></institution-wrap>Sao Paulo, 04024-002 Brazil </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0385 1941</institution-id><institution-id institution-id-type="GRID">grid.413562.7</institution-id><institution>Intensive Care Unit, </institution><institution>Hospital Israelita Albert Einstein, </institution></institution-wrap>Sao Paulo, 05652-900 Brazil </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9080 8521</institution-id><institution-id institution-id-type="GRID">grid.413471.4</institution-id><institution>Intensive Care Unit, </institution><institution>Hospital Sirio Libanes, </institution></institution-wrap>Sao Paulo, 01409-001 Brazil </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.440551.1</institution-id><institution>Present Address: Department of Bioscience and Biotechnology, </institution><institution>Banasthali Vidyapith, </institution></institution-wrap>Banasthali Tonk, 304022 Rajasthan India </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>16</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>16</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>16</volume>
<elocation-id>29</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Sepsis is a dysregulated host response to infection and a major cause of death worldwide. Respiratory tract infections account for most sepsis cases and depending on the place of acquisition, i.e., community or hospital acquired infection, differ in etiology, antimicrobial resistance and outcomes. Accordingly, the host response may be different in septic patients secondary to community-acquired pneumonia and hospital acquired pneumonia (HAP). Proteomic analysis is a useful approach to evaluate broad alterations in biological pathways that take place during sepsis. Here we evaluated plasma proteome changes in sepsis secondary to HAP.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">Plasma samples were obtained from patients (n = 27) at admission and after 7 days of follow-up, and were analyzed according to the patients’ outcomes. The patients’ proteome profiles were compared with healthy volunteers (n = 23). Pooled plasma samples were labeled with isobaric tag for relative and absolute quantitationand analyzed by LC–MS/MS. We used bioinformatics tools to find altered functions and pathways. Results were validated using biochemical estimations and ELISA tests.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">We identified 159 altered proteins in septic patients; most of them were common when comparing patients’ outcomes, both at admission and after 7 days. The top altered biological processes were acute inflammatory response, response to wounding, blood coagulation and homeostasis. Lipid metabolism emerged as the main altered function in patients, with HDL as a central node in the network analysis, interacting with downregulated proteins, such as APOA4, APOB, APOC1, APOL1, SAA4 and PON1. Validation tests showed reduced plasma levels of total cholesterol, HDL-C, LDL-C, non-HDL cholesterol, apolipoproteins ApoA1 and ApoB100, and Paraoxonase 1 in HAP patients.</p>
</sec>
<sec>
<title>Conclusion</title>
<p id="Par4">Proteomic analysis pointed to impairment of lipid metabolism as a major change in septic patients secondary to HAP, which was further validated by the reduced levels of cholesterol moieties and apolipoproteins in plasma. Our results stress the involvement of lipids in the pathogenesis of sepsis, which is in accordance with previous reports supporting the role of lipid moieties in pathogen toxin clearance and in modulating inflammatory responses.</p>
</sec>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1186/s12014-019-9252-2) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Sepsis</kwd>
<kwd>Proteome</kwd>
<kwd>Hospital-acquired pneumonia</kwd>
<kwd>Lipid metabolism</kwd>
<kwd>Cholesterol</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001807</institution-id>
<institution>Fundação de Amparo à Pesquisa do Estado de São Paulo</institution>
</institution-wrap>
</funding-source>
<award-id>2011/20401-4</award-id>
<award-id>2013/15636-8</award-id>
<principal-award-recipient>
<name>
<surname>Sharma</surname>
<given-names>Narendra Kumar</given-names>
</name>
<name>
<surname>Salomao</surname>
<given-names>Reinaldo</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003593</institution-id>
<institution>Conselho Nacional de Desenvolvimento Científico e Tecnológico</institution>
</institution-wrap>
</funding-source>
<award-id>305685/2011-2</award-id>
<principal-award-recipient>
<name>
<surname>Salomao</surname>
<given-names>Reinaldo</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par12">Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection [<xref ref-type="bibr" rid="CR1">1</xref>]. It is a major cause of morbidity and mortality worldwide, with over 30 million estimated cases annually leading to 5.3 million potential deaths [<xref ref-type="bibr" rid="CR2">2</xref>]. The burden of sepsis may be greater in developing countries [<xref ref-type="bibr" rid="CR3">3</xref>], as illustrated by the findings that one-third of intensive care beds in Brazil were occupied by septic patients, with a mortality rate of 55.7% [<xref ref-type="bibr" rid="CR4">4</xref>]. Sepsis may be secondary to community- or hospital-acquired infections, which differ in etiology, antimicrobial resistance and outcomes [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. The respiratory tract is the most common site of infection, accounting for more than half of the cases of sepsis in intensive care units (ICU) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
<p id="Par13">The pathogenesis of sepsis is complex and involves virulence factors from infectious microorganisms and the host defense immune system [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Inflammatory and anti-inflammatory responses are triggered in sepsis, exposing patients to the potential harmful effects of inflammation or immunosuppression [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Transcriptomics studies were pivotal in uncovering the broad derangements of the host following LPS exposure, trauma and sepsis [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>]. Proteins are the actual players in biological systems; hence, proteome changes have been investigated in clinical and experimental sepsis revealing that biological pathways, such as inflammatory, acute phase response, coagulation, complement, mitochondrial energy metabolism, and oxidative stress pathways are altered at the protein level [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p id="Par14">We have recently reported that the proteomes of patients with sepsis secondary to community acquired pneumonia (CAP) are altered, in which cytoskeleton, cellular assembly, movement, lipid metabolism and immune responses are dysregulated [<xref ref-type="bibr" rid="CR18">18</xref>]. Community and hospital acquired pneumonia are anticipated to present with different host responses during sepsis. A previous report evaluating a large cohort of CAP and HAP patients admitted to the ICU showed that patients with HAP presented with overexpressed genes involved in cell–cell junction remodeling, adhesion, and diapedesis, and an underexpressed type-I interferon signaling gene signature [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
<p id="Par15">In this study, we evaluated proteome changes in septic patients secondary to HAP, in which we evaluated samples at admission and after 7 days of treatment and accordingly to outcomes, in survivors and nonsurvivors. Proteins were quantified using the iTRAQ method and bioinformatic approaches were used for identifying molecular functions, biological processes and pathways. Processes related to lipid metabolism were then identified as the most altered in the plasma of HAP patients.</p>
</sec>
<sec id="Sec2">
<title>Material and methods</title>
<sec id="Sec3">
<title>Study design</title>
<p id="Par16">In the present study, patients with sepsis secondary to HAP were selected and analyzed based on outcomes, such as septic survival and septic nonsurvival at hospital discharge. Hospital acquired pneumonia (HAP) occurs 48 h or more after admission and does not appear to be incubating at the time of admission; ventilator-associated pneumonia (VAP) is a type of hospital-acquired pneumonia that occurs more than 02 days of mechanical ventilation [<xref ref-type="bibr" rid="CR20">20</xref>]. The patients’ plasma proteome profiles were compared with age and sex matched healthy volunteers.</p>
</sec>
<sec id="Sec4">
<title>Sample collection</title>
<p id="Par17">Blood samples were collected from healthy volunteers and from patients with severe sepsis/septic shock who were admitted into the ICUs of the participating hospitals after written informed consent was obtained from the participants or from their relatives. The prospective study was approved by the ethics committees of São Paulo Hospital (Study number 1477/06), Albert Einstein Hospital (Study number 07/549) and Sírio Libanês Hospital (Study number 2006/27). Patients with AIDS, immunosuppressive therapy or end stage chronic illness were excluded from the study. Fifty milliliters of blood was collected within 48 h of the first occurrence of organ dysfunction or septic shock (D0) and after 7 days of follow-up (D7). Plasma and blood cells were separated using a ficoll gradient (Ficoll-Paque PLUS; GE Healthcare Bio-Sciences AB, Uppsala, Sweden). A total of 425 septic patients were enrolled in the cohort, from which 27 septic patients, who had HAP as their primary source of infection and were older than 40 years of age, were selected for this study, 8 of whom survived and 19 of whom died during hospitalization (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Additionally, 23 healthy volunteers, who were matched by age and gender with the HAP patients, were selected from the 82 initially enrolled subjects for the study.<fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic flow chart of the patient enrollment and selection. Patients admitted to intensive care units with severe sepsis and/or septic shock were selected based on criteria that included blood sampling, source and site of infection, and were assigned to groups according to their outcomes (survivors and nonsurvivors)</p></caption><graphic id="MO1" xlink:href="12014_2019_9252_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec5">
<title>Plasma sample processing</title>
<p id="Par18">Plasma samples from septic patients were labeled as D0S and D7S, and D0NS and D7NS considering the day of collection and the outcomes, survivors (S) and non-survivors (NS). We estimated the protein content and pooled equal concentration of plasma protein from each individual sample to corresponding group before depletion. Healthy controls’ plasma samples were pooled in the same way.</p>
<p id="Par19">Plasma albumin and immunoglobulins are major components (&gt; 90%) of human blood and mask low abundant proteins. To unmask low abundant proteins, we depleted high abundant proteins using a proteome minor kit (BioRad, USA) and the depleted plasma samples were passed through a 3-kd filter with iTRAQ compatible buffer (Ab Sciex, USA). A total 100 μg of protein from all representative groups were transferred into separate tubes, and the volume was equalized with iTRAQ dissolution buffer. The cysteine disulfide bonds were reduced and alkylated using 50 mM TCEP and 200 mM methyl methanethiosulfate (MMTS). For protein digestion, 10 μg of trypsin was added to each vial, mixed and incubated at 37 °C overnight. The next day, the vial volume was reduced by SpeedVac and adjusted up to 30 μl using 1 M TEAB. A total of 60 μl of isopropanol was added to each iTRAQ reagent vial, mixed and quickly spun. The prepared iTRAQ reagent was added into the digested protein sample vial and incubated for 2 h at room temperature.</p>
</sec>
<sec id="Sec6">
<title>Sample fractionation using SCX chromatography</title>
<p id="Par20">To reduce the complexity, labeled peptides were fractionated using the SCX method. In brief, all sample vials were pooled into single vials and volume adjusted to pH &lt; 2.7 using SCX-A buffer and 1 M hydrochloric acid. Then, the sample was applied to a PolySULFOETHYL A column and washed with 100% SCX-A at a rate of one ml per minute for 30 min. The labeled peptide mix was separated as described previously [<xref ref-type="bibr" rid="CR18">18</xref>]. A total 20 fractions were collected and desalted using zip tip.</p>
</sec>
<sec id="Sec7">
<title>LC–MS/MS analysis</title>
<p id="Par21">Each fraction was applied to a nanoacquity UPLC nanoflow liquid chromatography system coupled with a Synapt G2 mass spectrometer (Waters, Milford, MA, USA). The fractions were further desalted in a trap column (180 µm × 2 cm, 5 µm, Waters, USA) at a flow rate of 8 µl/min for 5 min and then resolved on a C18 column (75 µm × 15 cm, 1.7 µm, Waters, USA) with an applied voltage of 3 kV. The peptides were separated using a linear gradient of 7–30% solvent B (90% acetonitrile in 0.1% formic acid) for 90 min with a flow rate of 250 nL/min. The MS data were acquired for the separated peptides in a data dependent manner from m/z 300 to 1600 Da with the three most abundant ions in the survey scan. For the MS/MS data, collision-induced dissociation (CID) mode was used with 1.5 s per spectra acquisition.</p>
<p id="Par22">After data acquisition, raw files were processed with mascot distiller (Matrix Science, USA), and all processed MS–MS peak list files were merged with mascot daemon. Then, the merged file was searched against the UniProt database (20,120 entries of reviewed proteins in humans). The parameters included trypsin as a protease (allowed one missed cleavage), iTRAQ label at N-terminus and lysine residues, cysteine modifications by MMTS were specified as fixed modifications, and oxidation of methionine was specified as a modification variable. The precursor and product ion mass error tolerance were fixed at 20 ppm and 0.1 Da, respectively. The peptide and protein data were extracted using a high peptide confidence (<italic>P</italic> ≤ 0.05) and a minimum of 2 peptides were used for protein identification. The false discovery rate (FDR) was calculated using decoy database searches. Peptides identified at 1% FDR were used for protein identification. The results from the mascot server were loaded into isobaricQ for iTRAQ quantitation [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
</sec>
<sec id="Sec8">
<title>Bioinformatic analysis of proteomics data</title>
<p id="Par23">The identified proteins were converted to gene names/gene symbols to further analyze gene ontology, altered functions and pathways.<list list-type="alpha-lower"><list-item><p id="Par24">Gene ontology annotations.</p></list-item></list>
</p>
<p id="Par25">Gene ontology (GO) annotation was carried out using Toppgene suite, as described earlier [<xref ref-type="bibr" rid="CR22">22</xref>]. In brief, a differentially expressed gene list was uploaded in the ToppFun section of Toppgene suite with an FDR B&amp;Y correction and a <italic>P</italic> value cut off 0.05. The resulting file, which contained altered molecular functions and biological processes, was analyzed.<list list-type="simple"><list-item><label>b.</label><p id="Par26">Function and pathway analysis.</p></list-item></list>
</p>
<p id="Par27">The gene list of identified proteins was uploaded into the Ingenuity pathway knowledge database (IPA) and the fold change cut off was set at ± 1.3 for further functional, pathway and regulatory network analyses. The significant altered functions and signaling pathways (<italic>P</italic> &lt; 0.05) were included.</p>
</sec>
<sec id="Sec9">
<title>Plasma protein quantitation and biochemical estimations</title>
<p id="Par28">To validate the proteomics data, we selected altered plasma proteins and cholesterol fractions for biochemical assays in individual samples from patients and healthy volunteers. For analysis, the COBAS c311 automated system was used. Cholesterol fractions and triglycerides were estimated, per the manufacturer’s protocol, using enzymatic and colorimetric methods (CHOL HICo Gen.2, HDL-C Gen.3 and TRIGL, Roche, USA). Plasma lipoprotein, apolipoprotein A-1 and apolipoprotein B were quantified, per the manufacturer’s protocols, using immunoturbidimetric methods (Tina-quant Lipoprotein (a) Gen.2, Tina-quant Apoliprotein A-1 ver.2 and Tina-quant Apoliprotein B ver.2, Roche, USA).</p>
<p id="Par29">PON-1 and haptoglobin plasma levels were quantified by ELISA. PON-1 was measured with a human total PON1 DuoSet<sup>®</sup> IC (DYC5816-2, R&amp;D Systems, USA) and haptoglobin with a human haptoglobin immunoassay Quantikine<sup>®</sup> ELISA (DHAPG0, R&amp;D Systems, USA), following the manufacturer’s instructions.</p>
</sec>
<sec id="Sec10">
<title>Statistical analysis</title>
<p id="Par30">The Shapiro–Wilk test was used to evaluate normality. For clinical data analysis, Fisher’s exact test was used for categorical variables and the unpaired <italic>t</italic> test was used for numerical variables. Differences in plasma levels of lipids and lipoproteins were analyzed by one-way ANOVA with the Bonferroni post hoc multiple comparison test. For PON-1 and haptoglobin ELISA analyses, the Kruskal–Wallis test was used to evaluate differences between patients and healthy volunteers. All differences were considered significant when a <italic>P</italic> value was ≤ 0.05. Analyses were performed using Graph Pad Prism 6 (GraphPad Software, Inc., USA).</p>
</sec>
</sec>
<sec id="Sec11">
<title>Results</title>
<sec id="Sec12">
<title>Clinical data</title>
<p id="Par31">Demographic and clinical data from patients are described in Table <xref ref-type="table" rid="Tab1">1</xref>. The average age of the septic patients was 62 years old and 70% of them were males. Most patients acquired pneumonia prior to ICU admission, presented with septic shock, and cardiovascular and respiratory dysfunctions were their main organ dysfunctions. Comparisons between the patients who survived and those who did not survive were not significantly different regarding the percentage of septic shock, severity scores, organ dysfunction or underlying conditions.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical variables and demographic data from septic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"></th><th align="left">Control (n = 23)</th><th align="left">Sepsis (n = 27)</th><th align="left">Survival (n = 8)</th><th align="left">Non-survival (n = 19)</th><th align="left"><italic>P</italic> value<sup>a</sup> S × NS</th></tr></thead><tbody><tr><td align="left">
<italic>Demographic data</italic>
</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Age, mean ± SD, year</td><td align="left">65 ± 14.6</td><td align="left">62.4 ± 12.8</td><td align="left">60 ± 15.8</td><td align="left">63.4 ± 11.6</td><td align="left">0.5357</td></tr><tr><td align="left">Sex (% of male)</td><td align="left">60.9</td><td align="left">70.4</td><td align="left">87.5</td><td align="left">63.2</td><td align="left">0.3645</td></tr><tr><td align="left">Place of acquired infection (%)</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left"> Prior to ICU</td><td align="left">NA</td><td align="left">77.8</td><td align="left">87.5</td><td align="left">73.68</td><td align="left">0.6334</td></tr><tr><td align="left"> ICU acquired</td><td align="left">NA</td><td align="left">22.2</td><td align="left">12.5</td><td align="left">26.32</td><td align="left"></td></tr><tr><td align="left">
<italic>Severity of disease</italic>
</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Septic shock (%)</td><td align="left">NA</td><td align="left">77.8</td><td align="left">87.5</td><td align="left">73.68</td><td align="left">0.6334</td></tr><tr><td align="left">Severity scores, mean ± SD</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left"> Apache II</td><td align="left">NA</td><td align="left">17.1 ± 6.5</td><td align="left">15.6 ± 7.6</td><td align="left">17.7 ± 6</td><td align="left">0.4483</td></tr><tr><td align="left"> SOFA</td><td align="left">NA</td><td align="left">8.3 ± 2.9</td><td align="left">8.0 ± 2.9</td><td align="left">8.4 ± 2.9</td><td align="left">0.7709</td></tr><tr><td align="left"> Delta-SOFA (D3-D0)</td><td align="left">NA</td><td align="left">(−) 0.4 ± 3.1</td><td align="left">(−) 1.9 ± 3.4</td><td align="left">0.7 ± 2.8</td><td align="left">0.0666</td></tr><tr><td align="left">Organ dysfunction (%)</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left"> Cardiovascular</td><td align="left">NA</td><td align="left">88.9</td><td align="left">87.5</td><td align="left">89.5</td><td align="left">1</td></tr><tr><td align="left"> Renal</td><td align="left">NA</td><td align="left">37</td><td align="left">37.5</td><td align="left">36.8</td><td align="left">1</td></tr><tr><td align="left"> Respiratory</td><td align="left">NA</td><td align="left">85.2</td><td align="left">75</td><td align="left">89.5</td><td align="left">0.5583</td></tr><tr><td align="left"> Hematological</td><td align="left">NA</td><td align="left">11.1</td><td align="left">0</td><td align="left">15.8</td><td align="left">0.5323</td></tr><tr><td align="left"> Hepatological</td><td align="left">NA</td><td align="left">33.3</td><td align="left">25</td><td align="left">36.8</td><td align="left">0.6758</td></tr><tr><td align="left"> Central nervous system</td><td align="left">NA</td><td align="left">44.4</td><td align="left">50</td><td align="left">42</td><td align="left">1</td></tr><tr><td align="left">
<italic>Underlying conditions</italic>
</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left">Chronic comorbidity (%)</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left"> AIDS</td><td align="left">NA</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">–</td></tr><tr><td align="left"> COPD</td><td align="left">NA</td><td align="left">15.4</td><td align="left">12.5</td><td align="left">16.7</td><td align="left">1</td></tr><tr><td align="left"> Diabetes</td><td align="left">NA</td><td align="left">30.8</td><td align="left">12.5</td><td align="left">38.9</td><td align="left">0.3602</td></tr><tr><td align="left"> Chronic renal disease</td><td align="left">NA</td><td align="left">7.7</td><td align="left">0</td><td align="left">11.1</td><td align="left">1</td></tr><tr><td align="left"> Cardiovascular insufficiency</td><td align="left">NA</td><td align="left">11.5</td><td align="left">0</td><td align="left">16.7</td><td align="left">0.5292</td></tr><tr><td align="left">Drugs (%)</td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td><td align="left"></td></tr><tr><td align="left"> Corticosteroids</td><td align="left">NA</td><td align="left">37</td><td align="left">50</td><td align="left">31.6</td><td align="left">0.4147</td></tr></tbody></table><table-wrap-foot><p><italic>S</italic> survivor, <italic>NS</italic> non-survivor, <italic>NA</italic> not applicable, <italic>SOFA</italic> Sequential [Sepsis-related] Organ Failure Assessment, <italic>COPD</italic> chronic obstructive pulmonary disease</p><p><sup>a</sup>Fisher’s exact test or unpaired t-test were applied to determine the <italic>P</italic> value when comparing survival and non-survival groups</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec13">
<title>Most altered proteins were common in the patients’ groups, despite their outcomes</title>
<p id="Par32">Using a quantitative proteomics approach, we selected 159 proteins for analysis after removal of albumin, immunoglobulin and their isoforms from a total of 220 proteins. At admission, 61 and 75 proteins were differentially expressed in the septic survivors and nonsurvivors, respectively, and 60 and 63 proteins were identified after 7 days in these groups when compared with healthy volunteers (Additional file <xref ref-type="media" rid="MOESM1">1</xref>). Venn diagram analysis enabled us to identify 14 proteins that were exclusively altered in survivors and 28 proteins in nonsurvivors, while 47 proteins were common in both groups at admission. Similarly, 20 proteins were identified exclusively in the survivors, 23 proteins were identified in the nonsurvivors and 40 proteins were identified that were common in both groups after 7 days (Fig. <xref ref-type="fig" rid="Fig2">2</xref>I, Additional file <xref ref-type="media" rid="MOESM2">2</xref>). We also analyzed the differentially expressed proteins from our previous community acquired pneumonia (CAP) results [<xref ref-type="bibr" rid="CR18">18</xref>] and found that the majority of the proteins were different between HAP and CAP. We found that, at admission, 26 proteins were common, while 38 and 35 proteins were specific to CAP and HAP survivors, respectively. Similarly, 33 proteins were common, while 35 and 42 proteins were specific to septic nonsurvivors in the CAP and HAP groups, respectively. Furthermore, after 7 days, 22 and 27 proteins were common in the survivor and nonsurvivor groups, while 57 and 38 were specific to the CAP and HAP survivors, and 48 and 36 proteins were specific to the CAP and HAP nonsurvivors, respectively (Fig. <xref ref-type="fig" rid="Fig2">2</xref>II, Additional file <xref ref-type="media" rid="MOESM2">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>A Venn diagram showing differential proteome expression between the septic patient groups. <bold>I</bold> shows the differential protein expression levels in survivors and nonsurvivors at admission (<bold>I</bold>a) and at D7 (<bold>I</bold>b), and the differential expression levels at D0 and D7 in survivors and in nonsurvivors (<bold>I</bold>c). <bold>II</bold> demonstrates the differential expression levels between community-acquired pneumonia and hospital-acquired pneumonia (a–d). CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia. D0S and D7S, admission and follow-up samples in survivors, and D0NS and D7 NS, admission and follow-up samples in nonsurvivors</p></caption><graphic id="MO2" xlink:href="12014_2019_9252_Fig2_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec14">
<title>Identification of altered pathways by gene ontology and ingenuity pathway analysis</title>
<p id="Par33">The gene names that corresponded with the differentially expressed identified proteins were generated for GO analysis. The top altered molecular functions included lipid binding and cytoskeleton protein binding in the survivors and nonsurvivors at admission (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a). The top altered biological processes were acute inflammatory response, response to wounding, blood coagulation and homeostasis in all septic patients, regardless of outcome or time of enrollment. We found that lipid localization, lipoprotein metabolic process, triglyceride metabolic process, VLDL particle remodeling and cell motility were altered in septic patients at admission, while humoral immune response was found after 7 days (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b). When analyzing cellular components, the proteins were mostly localized in blood microparticles, extra cellular space, HDL particles, plasma lipoprotein particles and protein lipid complexes (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c).<fig id="Fig3"><label>Fig. 3</label><caption><p>Gene ontology annotations for the identified differentially expressed proteins. Altered molecular functions (<bold>a</bold>), biological processes (<bold>b</bold>) and cellular components (<bold>c</bold>) in septic survivors and nonsurvivors at admission and after 7 days. The altered functions are represented as − log10 (<italic>P</italic> value) with the highlighted dots representing the group with maximum changes for a function. The white squares represent <italic>P</italic> values that were not included in the range selected for each analysis</p></caption><graphic id="MO3" xlink:href="12014_2019_9252_Fig3_HTML"></graphic></fig></p>
<p id="Par34">Similar results were obtained when analyzing canonical pathways with IPA. Pathways such as LXR/RXR activation, FXR/RXR activation (both related to lipid homeostasis [<xref ref-type="bibr" rid="CR23">23</xref>]), acute-phase response signaling and coagulation were found to be altered in all patient groups (Additional file <xref ref-type="media" rid="MOESM3">3</xref>).</p>
<p id="Par35">The top IPA scored disease and functions in the septic patients at admission were lipid metabolism, molecular transport and small molecule biochemistry (Additional file <xref ref-type="media" rid="MOESM4">4</xref>). Interaction network analysis of those functions show that HDL was a central node protein in the network, which interacts with downregulated proteins, such as APOA4, APOB, APOC1, APOL1, SAA4 and PON1. Upregulated proteins, such as CRP, HP, SAA1, FGA and LAMA3 also interacted with HDL, directly or indirectly (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a, b). After 7 days, different functions were top scored, but HDL remained a central node in the interaction network, both in the survivor and nonsurvivor groups (Fig. <xref ref-type="fig" rid="Fig4">4</xref>c, d, Additional file <xref ref-type="media" rid="MOESM4">4</xref>). Finally, functions related to lipid metabolism were impaired in all patients (Additional file <xref ref-type="media" rid="MOESM5">5</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Protein-protein interactions and functional networks. The red color represents upregulation and the green color represents downregulation. <bold>a</bold>–<bold>d</bold> corresponds to the D0 survivors, D0 nonsurvivors, D7 survivors and D7 nonsurvivors, respectively</p></caption><graphic id="MO4" xlink:href="12014_2019_9252_Fig4_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec15">
<title>Altered proteins related to lipid metabolism and other biological functions</title>
<p id="Par36">Proteomics analysis enabled us to identify several apolipoproteins that act on lipid transportation in septic patients. We identified decreased levels of Apo AI, Apo AIV, Apo B100, Apo CI, Apo CII, Apo CIII, Apo E and Apo L in septic patients. In addition to apolipoproteins, we identified other altered lipid binding proteins. Serum paraoxonase 1 (PON1), complement (C3) and corticosteroid-binding globulin (SERPINA6) were lower in patients than in controls. The expression levels of phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma (PIK3C2G), spectrin beta chain, nonerythrocytic 1 (SPTBN1) and C-reactive protein (CRP) were higher in septic patients than in controls at day 0 and day 7, while girdin (CCDC88A) was only higher at day 0. Haptoglobin (HP), which is related to both lipid metabolism and inflammation, and phospholipid-transporting ATPase IA (ATP8A1) were expressed at higher levels in the septic patients (Fig. <xref ref-type="fig" rid="Fig5">5</xref>). These proteins are involved in several functions, such as lipid homeostasis, lipoprotein metabolic processes, lipid transport, lipid localization, lipid catabolic processes, cholesterol transport, cholesterol homeostasis, cholesterol efflux, high-density lipoprotein particle remodeling and very-low-density lipoprotein particle remodeling.<fig id="Fig5"><label>Fig. 5</label><caption><p>Expression of lipid metabolism related proteins. The bar chart represents log<sub>2</sub>-fold-changes (patients vs. healthy volunteers) of altered proteins related to lipid metabolism. The dashed line represents the fold-change cut-off (log<sub>2</sub>-fold-change │0.3785│, corresponding to fold-change ± 1.3)</p></caption><graphic id="MO5" xlink:href="12014_2019_9252_Fig5_HTML"></graphic></fig>
</p>
<p id="Par37">In addition to lipid metabolism, proteins related to acute phase response were also altered in the patients. In addition to CRP and HP, alpha-1-antichymotrypsin (SERPINA3) and serum amyloid A-1 and A-2 proteins (SAA1 and SAA2) were upregulated in patients at admission and after 7 days of follow-up, while serum amyloid A-4 protein (SAA4) and prothrombin (F2) were downregulated. These and other dysregulated proteins are related to inflammation (SERPINA3, SAA1, SAA2, SAA4, HP, C3, C6, C8B, F2, CRP, APOC3, APOE and KNG1), complement (C3, C6, C8B and CRP) and coagulation (SAA1, KIF15, FGA, C3, APOB, FGG, APOE, F2, TTN, SERPIND1 and KNG1). The expression data are available in Additional file <xref ref-type="media" rid="MOESM1">1</xref>.</p>
<p id="Par38">To confirm the obtained results, we estimated the plasma levels of total cholesterol, HDL-C, LDL-C, triglycerides, ApoA-I, Apo B and lipoproteins in individual samples from patients and healthy volunteers. We found that the total cholesterol, non-HDL cholesterol, HDL-C, LDL-C, Apo AI and Apo B levels were significantly decreased in the septic patients. No significant changes were found in the total triglyceride and lipoprotein levels. Also related to lipid metabolism, the levels of serum paraoxonase (PON1) were decreased in the septic patients. In contrast, the HP levels tended to be increased in the septic patients (Table <xref ref-type="table" rid="Tab2">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Estimation of lipid moieties and proteins in blood plasma</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Plasma level median (IQR)</th><th align="left" rowspan="2">Control (n = 10)</th><th align="left" colspan="2">Survivor patients (n = 6)</th><th align="left" colspan="2">Non-survivor patients (n = 11)</th></tr><tr><th align="left">D0</th><th align="left">D7</th><th align="left">D0</th><th align="left">D7</th></tr></thead><tbody><tr><td align="left">Total cholesterol (mg/dL)</td><td align="left">198</td><td align="left">90.5*</td><td align="left">110.5*</td><td align="left">105*</td><td align="left">104*</td></tr><tr><td align="left"></td><td align="left">(176.5–245.5)</td><td align="left">(79–121.5)</td><td align="left">(103–145.5)</td><td align="left">(86–125)</td><td align="left">(91–150)</td></tr><tr><td align="left">HDL-C (mg/dL)</td><td align="left">54.5</td><td align="left">20*</td><td align="left">33.5*</td><td align="left">23*</td><td align="left">20*</td></tr><tr><td align="left"></td><td align="left">(45.8–59.3)</td><td align="left">(7.8–33.5)</td><td align="left">(17.8–42.5)</td><td align="left">(21–35)</td><td align="left">(12–48)</td></tr><tr><td align="left">LDL-C (mg/dL)</td><td align="left">121.5</td><td align="left">51*</td><td align="left">68*</td><td align="left">56*</td><td align="left">59*</td></tr><tr><td align="left"></td><td align="left">(89–161.3)</td><td align="left">(39.8–79)</td><td align="left">(56.3–80)</td><td align="left">(52–68)</td><td align="left">(52–83)</td></tr><tr><td align="left">Non-HDL-C (mg/dL)</td><td align="left">148</td><td align="left">70*</td><td align="left">86*</td><td align="left">79*</td><td align="left">86*</td></tr><tr><td align="left"></td><td align="left">(121.8–190.3)</td><td align="left">(54–99.5)</td><td align="left">(70–109.3)</td><td align="left">(72–97)</td><td align="left">(77–103)</td></tr><tr><td align="left">Triglycerides (mg/dL)</td><td align="left">144</td><td align="left">89.5</td><td align="left">103</td><td align="left">125</td><td align="left">127</td></tr><tr><td align="left"></td><td align="left">(115–184.5)</td><td align="left">(64.5–165.3)</td><td align="left">(67.5–200)</td><td align="left">(85–179)</td><td align="left">(106–177)</td></tr><tr><td align="left">APO A-I (mg/dL)</td><td align="left">151.5</td><td align="left">65*</td><td align="left">92*</td><td align="left">67*</td><td align="left">67*</td></tr><tr><td align="left"></td><td align="left">(139.8–177.5)</td><td align="left">(45.8–88.3)</td><td align="left">(58.8–109.8)</td><td align="left">(63–88)</td><td align="left">(49–91)</td></tr><tr><td align="left">APO B (mg/dL)</td><td align="left">104</td><td align="left">56.5*</td><td align="left">72.5*</td><td align="left">71*</td><td align="left">77</td></tr><tr><td align="left"></td><td align="left">(85.5–141.5)</td><td align="left">(50.5–73)</td><td align="left">(68.3–78.5)</td><td align="left">(48–86)</td><td align="left">(71–112)</td></tr><tr><td align="left">Lipoproteins (mg/dL)</td><td align="left">15.5</td><td align="left">5.8</td><td align="left">5.9</td><td align="left">6.5</td><td align="left">13.2</td></tr><tr><td align="left"></td><td align="left">(8.6–26.9)</td><td align="left">(3.27–25)</td><td align="left">(4.12–31.6)</td><td align="left">(4.9–14.9)</td><td align="left">(5.8–36.8)</td></tr><tr><td align="left">PON 1 (ng/mL)<sup>#</sup></td><td align="left">210.2</td><td align="left">106.3*</td><td align="left">111.9*</td><td align="left">110.2*</td><td align="left">113.8*</td></tr><tr><td align="left"></td><td align="left">(170.1–313.7)</td><td align="left">(78.9–141.5)</td><td align="left">(83.6–189.4)</td><td align="left">(93.5–183.6)</td><td align="left">(98.5–174.9)</td></tr><tr><td align="left">Haptoglobin (mg/mL)<sup>#</sup></td><td align="left">0.98</td><td align="left">1.6</td><td align="left">1.4</td><td align="left">1.3</td><td align="left">1.5</td></tr><tr><td align="left"></td><td align="left">(0.7–1.3)</td><td align="left">(0.9–2.1)</td><td align="left">(0.8–1.7)</td><td align="left">(0.9–1.7)</td><td align="left">(1.2–1.6)</td></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> ≤ 0.05 when comparing patients to healthy volunteers by Kruskal–Wallis test or one-way ANOVA with Bonferroni’s post hoc multiple comparison test</p><p><sup>#</sup>PON 1 measurements were performed in 11 individuals in control group, 11 in survivors and 12 in non-survivors group; haptoglobin measurements were performed in 8 controls, 4 survivors patients and 10 non-survivors patients</p></table-wrap-foot></table-wrap>
</p>
</sec>
</sec>
<sec id="Sec16">
<title>Discussion</title>
<p id="Par39">Sepsis is a major cause of death in ICUs and the respiratory tract is the main primary infection site in septic patients. We previously evaluated the plasma proteome of patients with sepsis secondary to community-acquired pneumonia [<xref ref-type="bibr" rid="CR18">18</xref>]. Here, we reported on plasma proteome alterations in patients with sepsis secondary to hospital-acquired pneumonia.</p>
<p id="Par40">Different bioinformatics analyses revealed changes in acute phase response, inflammatory response and blood coagulation in this septic patient cohort, as previously described [<xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref>]. Nevertheless, lipid metabolism processes emerged as the main changes in the septic patients compared with healthy volunteers. These observations do not differ very much from what we found in the CAP patients [<xref ref-type="bibr" rid="CR18">18</xref>], despite the fact that most altered proteins in the HAP patients were distinct from the CAP patients. A recent study that compared host responses to CAP and HAP described similar genomic alterations in both clinical groups, despite differences in the pathogens and conditions that lead to infection in each case [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
<p id="Par41">HDL was found to be a central node in the interaction network analysis in all patient groups, regardless of outcome or the time of enrollment. It is well known that, depending on the protein and lipid composition, HDL can develop an anti-inflammatory or an inflammatory profile [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]; it is also well known that both infection and sepsis decrease the plasma levels of HDL in patients [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. HDL with an inflammatory profile is related to SOFA score [<xref ref-type="bibr" rid="CR31">31</xref>] and elder patients with sepsis were reported to present with a lower cholesterol efflux capacity, which is the main function of HDL, and a higher HDL inflammatory index [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
<p id="Par42">In our proteomics results, we found decreased expression of PON1 and the apolipoproteins related to HDL (APO A1, APO C and APO E), and increased levels of HP and SAA1/SAA2. Additionally, we observed by biochemical analysis that the total cholesterol, HDL, APO A1 and PON 1 levels were decreased in the patients. These findings are similar to our previously reported changes in patients with sepsis and CAP [<xref ref-type="bibr" rid="CR18">18</xref>] and are in accordance with the literature, which points to HDL turning into a pro-inflammatory mediator in septic patients. The reduction in APO A1 levels and increase of SAA levels is a characteristic change in the so-called acute-phase HDL [<xref ref-type="bibr" rid="CR28">28</xref>] and was previously observed in sepsis [<xref ref-type="bibr" rid="CR33">33</xref>]; furthermore, decreased APO A1 levels are related with mortality in septic patients [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
<p id="Par43">Paraoxonase 1 is a component of HDL that acts as an antioxidant enzyme [<xref ref-type="bibr" rid="CR35">35</xref>]. The reduction of PON1 in HDL is related to inflammatory conditions [<xref ref-type="bibr" rid="CR35">35</xref>] and it was reported that PON1 has lower activity in septic patients, which is normalized after recovery [<xref ref-type="bibr" rid="CR36">36</xref>]. Additionally, nonsurvivor patients presented with even lower activities than those who survived [<xref ref-type="bibr" rid="CR37">37</xref>]. In addition, we found increased expression of HP in HAP patients, although this result was not significant in the validation step. However, data in the literature corroborate our observation. For example, HP was found to be a good biomarker for sepsis development in trauma patients [<xref ref-type="bibr" rid="CR38">38</xref>]. HP is a scavenger of free hemoglobin [<xref ref-type="bibr" rid="CR39">39</xref>] and it may play a protective role in septic patients, as they can present with elevated levels of cell-free hemoglobin [<xref ref-type="bibr" rid="CR40">40</xref>]. In contrast, HP when associated with HDL can contribute to pro inflammatory responses [<xref ref-type="bibr" rid="CR41">41</xref>]. It was described that HP binding to ApoA1 impairs HDL function and that peptides that displace HP from ApoA1 can reverse this phenotype [<xref ref-type="bibr" rid="CR42">42</xref>]. Additionally, HP gene polymorphisms were related to altered levels of LDL and CRP, and the ApoA1/ApoA2 ratio in plasma [<xref ref-type="bibr" rid="CR43">43</xref>]. Nevertheless, binding of HP to ApoA1 during an acute phase response can protect ApoA1 from oxidative damage [<xref ref-type="bibr" rid="CR44">44</xref>].</p>
<p id="Par44">Sepsis and systemic inflammation decrease not only the levels of HDL but also promote hypocholesterolemia, with lower levels of total cholesterol and LDL [<xref ref-type="bibr" rid="CR28">28</xref>]. We observed reduced levels of total cholesterol in HAP patients, which was similar to what was observed in CAP patients. It was reported that hypocholesterolemia is related with severity and that cholesterol levels increase during convalescence in severely injured patients [<xref ref-type="bibr" rid="CR45">45</xref>]. We also observed decreased levels of Apo B, LDL and non-HDL cholesterol in HAP patients, while in our previous work with CAP, the levels of these plasma components were not significantly lower than controls [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
<p id="Par45">Similar to HDL, LDL has an important role in neutralizing pathogen toxins, such as LPS [<xref ref-type="bibr" rid="CR28">28</xref>]. Low LDL levels were associated with the presence of fever and sepsis in hospitalized patients [<xref ref-type="bibr" rid="CR46">46</xref>] and with long-terms rates of sepsis [<xref ref-type="bibr" rid="CR47">47</xref>]. Additionally, it was observed that even with LDL levels below normal, septic patients present with higher levels of oxidized LDL, which is pro inflammatory [<xref ref-type="bibr" rid="CR48">48</xref>]. The major apolipoprotein of LDL is Apo B, which was reduced in septic patients in our proteomic results. Apo B levels was reported to be increased after <italic>Escherichia coli</italic> sepsis in an experimental model [<xref ref-type="bibr" rid="CR49">49</xref>]; in human sepsis, LPS-binding protein—that interacts with ApoB was found to be associated with LDL and VLDL particles [<xref ref-type="bibr" rid="CR50">50</xref>]. In this context, our results point to LDL as contributing to inflammation and with impaired scavenger capacity. It is noteworthy, however, that while reduced LDL production is related to a complicated prognosis, LDL clearance can improve survival [<xref ref-type="bibr" rid="CR51">51</xref>].</p>
<p id="Par46">In conclusion, our proteomic study stresses the lipid metabolism as a major altered function in the plasma of patients with sepsis secondary to hospital acquired pneumonia, which is in accordance with previous reports supporting the role of lipid moieties in pathogen toxin clearance and in modulating inflammatory responses. Interestingly, HDL-C and cholesterol levels have been associated with risk of nosocomial infection acquisition [<xref ref-type="bibr" rid="CR52">52</xref>]. These results reinforce the importance of lipid metabolism in sepsis pathogenesis and as a possible therapeutic target.</p>
<p id="Par47">Our study has some limitations. We used pools of samples to run proteomics for the different groups of patients, D0S and D7S, and D0NS and D7NS, and healthy volunteers. The characteristics and the limited number of tags available for quantification in the iTRAQ protocol favours the conduction of the experiments with pooled samples. Several other clinical proteomics studies with iTRAQ were performed with pooled samples [<xref ref-type="bibr" rid="CR53">53</xref>]. However, we are aware of the limitations of using pooled samples. To overcome these limitations, for validation, we used individual samples for representative groups. By choosing healthy volunteers as controls, it is not possible to differentiate the changes in plasma proteome that are specific for the septic patients secondary to HAP from those that take place in another critical illnesses. Furthermore, some underlying conditions not covered in our survey could be present in patients and influenced the proteome changes we are reporting.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Additional files</title>
<sec id="Sec17">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12014_2019_9252_MOESM1_ESM.xls"><caption><p><bold>Additional file 1.</bold> Proteomics Quantification - Raw and processed data.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12014_2019_9252_MOESM2_ESM.docx"><caption><p><bold>Additional file 2.</bold> The details of the common and differentially expressed proteins in different groups corresponding to Venn diagram. CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia. D0S and D7S, admission and follow-up samples in survivors. D0NS and D7 NS, admission and follow-up samples in non-survivors.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12014_2019_9252_MOESM3_ESM.docx"><caption><p><bold>Additional file 3.</bold> IPA canonical pathway analysis in septic patients. A refers to altered canonical pathway in D0 survivors; B refers to D0 non-survivors; C refers to D7 survivors; and D refers to D7 non-survivors. Enriched canonical pathways were identified from the IPA library using Fisher’s exact test adjusted for multiple hypothesis testing with the Benjamini- Hochberg correction.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12014_2019_9252_MOESM4_ESM.docx"><caption><p><bold>Additional file 4.</bold> Functional protein interaction network for septic patients. The bold symbols represent the proteins identified in our study with their functions. The green arrow shows decreased expression and red arrow show increased expression compared with healthy volunteers.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12014_2019_9252_MOESM5_ESM.docx"><caption><p><bold>Additional file 5.</bold> Functional analysis curated by Ingenuity Pathway Analyses. Prediction of altered functions based on activation Z-score. A score lower than -2 or higher than 2 predicts decreased or increased activation for each function. S: survivor. NS: non-survivor.</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>CAP</term>
<def>
<p id="Par5">community-acquired pneumonia</p>
</def>
</def-item>
<def-item>
<term>HAP</term>
<def>
<p id="Par6">hospital-acquired pneumonia</p>
</def>
</def-item>
<def-item>
<term>iTRAQ</term>
<def>
<p id="Par7">isobaric tag for relative and absolute quantitation</p>
</def>
</def-item>
<def-item>
<term>TCEP</term>
<def>
<p id="Par8">tris(2-carboxyethyl)phosphine</p>
</def>
</def-item>
<def-item>
<term>TEAB</term>
<def>
<p id="Par9">triethylammonium bicarbonate</p>
</def>
</def-item>
<def-item>
<term>IPA</term>
<def>
<p id="Par10">ingenuity pathway analysis</p>
</def>
</def-item>
<def-item>
<term>SOFA</term>
<def>
<p id="Par11">sequential [sepsis-related] organ failure assessment</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher's Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>Narendra Kumar Sharma and Bianca Lima Ferreira contributed equally to the paper</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank Antonia Machado from the Central Laboratory of Hospital São Paulo for providing the biochemical estimations in the plasma samples.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>NS and RS conceived the study. NS, AT and RS designed the experiments. AB, MA and LA enrolled the patients and obtained clinical data. NS, BF, MB and RT performed the experiments. NS, BF and RS interpreted the results. NS, BF and RS wrote the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>This study was supported by the Sao Paulo Research Foundation (FAPESP) (2011/20401-4, 2013/15636-8) and by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (305685/2011-2).</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in the manuscript and the additional files. Any further information is available from the corresponding author on request.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par48">This study was approved by the ethics committees of São Paulo Hospital (Study number 1477/06), Albert Einstein Hospital (Study number 07/549) and Sírio Libanês Hospital (Study number 2006/27). Written informed consent was obtained from participants or from their relatives.</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par49">Not applicable.</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par50">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Deutschman</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Seymour</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Shankar-Hari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Annane</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title>
<source/>JAMA
          <year>2016</year>
<volume>315</volume>
<issue>8</issue>
<fpage>801</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
<pub-id pub-id-type="pmid">26903338</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleischmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scherag</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Adhikari</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Hartog</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Tsaganos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schlattmann</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations</article-title>
<source/>Am J Respir Crit Care Med
          <year>2016</year>
<volume>193</volume>
<issue>3</issue>
<fpage>259</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201504-0781OC</pub-id>
<pub-id pub-id-type="pmid">26414292</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adhikari</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bhagwanjee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rubenfeld</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Critical care and the global burden of critical illness in adults</article-title>
<source/>Lancet
          <year>2010</year>
<volume>376</volume>
<issue>9749</issue>
<fpage>1339</fpage>
<lpage>1346</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(10)60446-1</pub-id>
<pub-id pub-id-type="pmid">20934212</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machado</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Cavalcanti</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Bozza</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Angotti Carrara</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Sousa</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study</article-title>
<source/>Lancet Infect Dis
          <year>2017</year>
<volume>17</volume>
<issue>11</issue>
<fpage>1180</fpage>
<lpage>1189</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(17)30322-5</pub-id>
<pub-id pub-id-type="pmid">28826588</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salomao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Castelo Filho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pignatari</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wey</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>Nosocomial and community acquired bacteremia: variables associated with outcomes</article-title>
<source/>Rev Paul Med
          <year>1993</year>
<volume>111</volume>
<issue>6</issue>
<fpage>456</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="pmid">8052793</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biedenbach</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Moet</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002)</article-title>
<source/>Diagn Microbiol Infect Dis
          <year>2004</year>
<volume>50</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2004.05.003</pub-id>
<pub-id pub-id-type="pmid">15380279</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pien</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Sundaram</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Raoof</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Mirrett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>CW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The clinical and prognostic importance of positive blood cultures in adults</article-title>
<source/>Am J Med
          <year>2010</year>
<volume>123</volume>
<issue>9</issue>
<fpage>819</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="doi">10.1016/j.amjmed.2010.03.021</pub-id>
<pub-id pub-id-type="pmid">20800151</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincent</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Rello</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Anzueto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>International study of the prevalence and outcomes of infection in intensive care units</article-title>
<source/>JAMA
          <year>2009</year>
<volume>302</volume>
<issue>21</issue>
<fpage>2323</fpage>
<lpage>2329</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2009.1754</pub-id>
<pub-id pub-id-type="pmid">19952319</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Poll</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Opal</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Host-pathogen interactions in sepsis</article-title>
<source/>Lancet Infect Dis
          <year>2008</year>
<volume>8</volume>
<issue>1</issue>
<fpage>32</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(07)70265-7</pub-id>
<pub-id pub-id-type="pmid">18063412</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salomao</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brunialti</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Rapozo</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Baggio-Zappia</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Galanos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Freudenberg</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Bacterial sensing, cell signaling, and modulation of the immune response during sepsis</article-title>
<source/>Shock
          <year>2012</year>
<volume>38</volume>
<issue>3</issue>
<fpage>227</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1097/SHK.0b013e318262c4b0</pub-id>
<pub-id pub-id-type="pmid">22777111</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angus</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>van der Poll</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Severe sepsis and septic shock</article-title>
<source/>N Engl J Med
          <year>2013</year>
<volume>369</volume>
<issue>9</issue>
<fpage>840</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMra1208623</pub-id>
<pub-id pub-id-type="pmid">23984731</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hotchkiss</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Monneret</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Payen</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach</article-title>
<source/>Lancet Infect Dis
          <year>2013</year>
<volume>13</volume>
<issue>3</issue>
<fpage>260</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(13)70001-X</pub-id>
<pub-id pub-id-type="pmid">23427891</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvano</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Felciano</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>RJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A network-based analysis of systemic inflammation in humans</article-title>
<source/>Nature
          <year>2005</year>
<volume>437</volume>
<issue>7061</issue>
<fpage>1032</fpage>
<lpage>1037</lpage>
<pub-id pub-id-type="doi">10.1038/nature03985</pub-id>
<pub-id pub-id-type="pmid">16136080</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Genome-wide transcription profiling of human sepsis: a systematic review</article-title>
<source/>Crit Care
          <year>2010</year>
<volume>14</volume>
<issue>6</issue>
<fpage>R237</fpage>
<pub-id pub-id-type="doi">10.1186/cc9392</pub-id>
<pub-id pub-id-type="pmid">21190579</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mindrinos</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Seok</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cuschieri</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cuenca</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A genomic storm in critically injured humans</article-title>
<source/>J Exp Med
          <year>2011</year>
<volume>208</volume>
<issue>13</issue>
<fpage>2581</fpage>
<lpage>2590</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20111354</pub-id>
<pub-id pub-id-type="pmid">22110166</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>The role of proteomics in understanding biological mechanisms of sepsis</article-title>
<source/>Proteom Clin Appl
          <year>2014</year>
<volume>8</volume>
<issue>1–2</issue>
<fpage>35</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1002/prca.201300101</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Salomao</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Sepsis through the eyes of proteomics: the progress in the last decade</article-title>
<source/>Shock
          <year>2017</year>
<volume>47</volume>
<issue>1S Suppl 1</issue>
<fpage>17</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1097/SHK.0000000000000698</pub-id>
<pub-id pub-id-type="pmid">27454376</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Tashima</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Brunialti</surname>
<given-names>MKC</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Torquato</surname>
<given-names>RJS</given-names>
</name>
<name>
<surname>Mortara</surname>
<given-names>RA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomic study revealed cellular assembly and lipid metabolism dysregulation in sepsis secondary to community-acquired pneumonia</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>15606</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-15755-1</pub-id>
<pub-id pub-id-type="pmid">29142235</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Vught</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Scicluna</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Wiewel</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hoogendijk</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Klein Klouwenberg</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Franitza</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparative analysis of the host response to community-acquired and hospital-acquired pneumonia in critically ill patients</article-title>
<source/>Am J Respir Crit Care Med
          <year>2016</year>
<volume>194</volume>
<issue>11</issue>
<fpage>1366</fpage>
<lpage>1374</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.201602-0368OC</pub-id>
<pub-id pub-id-type="pmid">27267747</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<mixed-citation publication-type="other">Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Event. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nhsn/PDFs/pscManual/6pscVAPcurrent.pdf">https://www.cdc.gov/nhsn/PDFs/pscManual/6pscVAPcurrent.pdf</ext-link>. Accessed 08 Apr 2019.</mixed-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arntzen</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Koehler</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Barsnes</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Berven</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Treumann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thiede</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>IsobariQ: software for isobaric quantitative proteomics using IPTL, iTRAQ, and TMT</article-title>
<source/>J Proteome Res
          <year>2011</year>
<volume>10</volume>
<issue>2</issue>
<fpage>913</fpage>
<lpage>920</lpage>
<pub-id pub-id-type="doi">10.1021/pr1009977</pub-id>
<pub-id pub-id-type="pmid">21067241</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Sethy</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Bhargava</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Comparative proteome analysis reveals differential regulation of glycolytic and antioxidant enzymes in cortex and hippocampus exposed to short-term hypobaric hypoxia</article-title>
<source/>J Proteom
          <year>2013</year>
<volume>79</volume>
<fpage>277</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1016/j.jprot.2012.12.020</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dahlman-Wright</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Liver X receptor in cholesterol metabolism</article-title>
<source/>J Endocrinol
          <year>2010</year>
<volume>204</volume>
<issue>3</issue>
<fpage>233</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1677/JOE-09-0271</pub-id>
<pub-id pub-id-type="pmid">19837721</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Press</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Trauner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The liver in sepsis: patterns of response and injury</article-title>
<source/>Curr Opin Crit Care
          <year>2013</year>
<volume>19</volume>
<issue>2</issue>
<fpage>123</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1097/MCC.0b013e32835eba6d</pub-id>
<pub-id pub-id-type="pmid">23448974</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>The inflammatory response in sepsis</article-title>
<source/>Trends Immunol
          <year>2013</year>
<volume>34</volume>
<issue>3</issue>
<fpage>129</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1016/j.it.2012.09.004</pub-id>
<pub-id pub-id-type="pmid">23036432</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van der Poll</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Coagulation and sepsis</article-title>
<source/>Thromb Res
          <year>2017</year>
<volume>149</volume>
<fpage>38</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.thromres.2016.11.007</pub-id>
<pub-id pub-id-type="pmid">27886531</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Lenten</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Hama</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>de Beer</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Stafforini</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Prescott</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures</article-title>
<source/>J Clin Investig
          <year>1995</year>
<volume>96</volume>
<issue>6</issue>
<fpage>2758</fpage>
<lpage>2767</lpage>
<pub-id pub-id-type="doi">10.1172/JCI118345</pub-id>
<pub-id pub-id-type="pmid">8675645</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khovidhunkit</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Memon</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Shigenaga</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Feingold</surname>
<given-names>KR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host</article-title>
<source/>J Lipid Res
          <year>2004</year>
<volume>45</volume>
<issue>7</issue>
<fpage>1169</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1194/jlr.R300019-JLR200</pub-id>
<pub-id pub-id-type="pmid">15102878</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hinds</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Thiemermann</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications</article-title>
<source/>Shock
          <year>2004</year>
<volume>21</volume>
<issue>3</issue>
<fpage>210</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1097/01.shk.0000111661.09279.82</pub-id>
<pub-id pub-id-type="pmid">14770033</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cirstea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walley</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Brunham</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Genga</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis</article-title>
<source/>J Crit Care
          <year>2017</year>
<volume>38</volume>
<fpage>289</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcrc.2016.11.041</pub-id>
<pub-id pub-id-type="pmid">28013095</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guirgis</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Dodani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leeuwenburgh</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moldawer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bowman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kalynych</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HDL inflammatory index correlates with and predicts severity of organ failure in patients with sepsis and septic shock</article-title>
<source/>PLoS ONE
          <year>2018</year>
<volume>13</volume>
<issue>9</issue>
<fpage>e0203813</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0203813</pub-id>
<pub-id pub-id-type="pmid">30216360</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guirgis</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Leeuwenburgh</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Grijalva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bowman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kalynych</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moldawer</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HDL cholesterol efflux is impaired in older patients with early sepsis: a subanalysis of a prospective pilot study</article-title>
<source/>Shock
          <year>2018</year>
<volume>50</volume>
<issue>1</issue>
<fpage>66</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1097/SHK.0000000000001030</pub-id>
<pub-id pub-id-type="pmid">29049133</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Leeuwen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Heezius</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Dallinga</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>van Strijp</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Verhoef</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Kessel</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Lipoprotein metabolism in patients with severe sepsis</article-title>
<source/>Crit Care Med
          <year>2003</year>
<volume>31</volume>
<issue>5</issue>
<fpage>1359</fpage>
<lpage>1366</lpage>
<pub-id pub-id-type="doi">10.1097/01.CCM.0000059724.08290.51</pub-id>
<pub-id pub-id-type="pmid">12771603</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chien</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Jerng</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis</article-title>
<source/>Crit Care Med
          <year>2005</year>
<volume>33</volume>
<issue>8</issue>
<fpage>1688</fpage>
<lpage>1693</lpage>
<pub-id pub-id-type="doi">10.1097/01.CCM.0000171183.79525.6B</pub-id>
<pub-id pub-id-type="pmid">16096442</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackness</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mackness</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles</article-title>
<source/>Gene
          <year>2015</year>
<volume>567</volume>
<issue>1</issue>
<fpage>12</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2015.04.088</pub-id>
<pub-id pub-id-type="pmid">25965560</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novak</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vavrova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kodydkova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>F</given-names>
<suffix>Sr</suffix>
</name>
<name>
<surname>Hynkova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zak</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased paraoxonase activity in critically ill patients with sepsis</article-title>
<source/>Clin Exp Med
          <year>2010</year>
<volume>10</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1007/s10238-009-0059-8</pub-id>
<pub-id pub-id-type="pmid">19760042</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Draganov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Teiber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bisgaier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nemzek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Remick</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PON1 and oxidative stress in human sepsis and an animal model of sepsis</article-title>
<source/>Adv Exp Med Biol
          <year>2010</year>
<volume>660</volume>
<fpage>89</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-60761-350-3_9</pub-id>
<pub-id pub-id-type="pmid">20221873</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rittirsch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schoenborn</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lindig</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wanner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sprengel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gunkel</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improvement of prognostic performance in severely injured patients by integrated clinico-transcriptomics: a translational approach</article-title>
<source/>Crit Care
          <year>2015</year>
<volume>19</volume>
<fpage>414</fpage>
<pub-id pub-id-type="doi">10.1186/s13054-015-1127-y</pub-id>
<pub-id pub-id-type="pmid">26607226</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersen</surname>
<given-names>CBF</given-names>
</name>
<name>
<surname>Stodkilde</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Saederup</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Kuhlee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raunser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Graversen</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Haptoglobin</article-title>
<source/>Antioxid Redox Signal
          <year>2017</year>
<volume>26</volume>
<issue>14</issue>
<fpage>814</fpage>
<lpage>831</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2016.6793</pub-id>
<pub-id pub-id-type="pmid">27650279</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janz</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Bastarache</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Sills</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wickersham</surname>
<given-names>N</given-names>
</name>
<name>
<surname>May</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>GR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between haptoglobin, hemopexin and mortality in adults with sepsis</article-title>
<source/>Crit Care
          <year>2013</year>
<volume>17</volume>
<issue>6</issue>
<fpage>R272</fpage>
<pub-id pub-id-type="doi">10.1186/cc13108</pub-id>
<pub-id pub-id-type="pmid">24225252</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grijalva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barbour</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Navab</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein</article-title>
<source/>J Biol Chem
          <year>2009</year>
<volume>284</volume>
<issue>27</issue>
<fpage>18292</fpage>
<lpage>18301</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.017202</pub-id>
<pub-id pub-id-type="pmid">19433579</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spagnuolo</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Di Stasi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Maresca</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cigliano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>D’Andrea</surname>
<given-names>LD</given-names>
</name>
</person-group>
<article-title>Analysis of the haptoglobin binding region on the apolipoprotein A-I-derived P2a peptide</article-title>
<source/>J Pept Sci
          <year>2013</year>
<volume>19</volume>
<issue>4</issue>
<fpage>220</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1002/psc.2487</pub-id>
<pub-id pub-id-type="pmid">23420675</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wuyts</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hetet</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grandchamp</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Delanghe</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Novel haptoglobin insertion/deletion polymorphism is associated with the lipid profile and C-reactive protein (CRP) concentration</article-title>
<source/>Clin Chem Lab Med
          <year>2002</year>
<volume>40</volume>
<issue>5</issue>
<fpage>469</fpage>
<lpage>474</lpage>
<pub-id pub-id-type="doi">10.1515/CCLM.2002.081</pub-id>
<pub-id pub-id-type="pmid">12113290</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvatore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cigliano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bucci</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Corpillo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carlucci</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Haptoglobin binding to apolipoprotein A-I prevents damage from hydroxyl radicals on its stimulatory activity of the enzyme lecithin-cholesterol acyl-transferase</article-title>
<source/>Biochemistry
          <year>2007</year>
<volume>46</volume>
<issue>39</issue>
<fpage>11158</fpage>
<lpage>11168</lpage>
<pub-id pub-id-type="doi">10.1021/bi7006349</pub-id>
<pub-id pub-id-type="pmid">17824618</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunham</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Fealk</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Sever</surname>
<given-names>WE</given-names>
<suffix>3rd</suffix>
</name>
</person-group>
<article-title>Following severe injury, hypocholesterolemia improves with convalescence but persists with organ failure or onset of infection</article-title>
<source/>Crit Care
          <year>2003</year>
<volume>7</volume>
<issue>6</issue>
<fpage>R145</fpage>
<lpage>R153</lpage>
<pub-id pub-id-type="doi">10.1186/cc2382</pub-id>
<pub-id pub-id-type="pmid">14624689</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shor</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wainstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Oz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boaz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matas</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fux</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy</article-title>
<source/>Ann Clin Lab Sci
          <year>2007</year>
<volume>37</volume>
<issue>4</issue>
<fpage>343</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="pmid">18000291</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guirgis</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Donnelly</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Dodani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Safford</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Levitan</surname>
<given-names>EB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cholesterol levels and long-term rates of community-acquired sepsis</article-title>
<source/>Crit Care
          <year>2016</year>
<volume>20</volume>
<issue>1</issue>
<fpage>408</fpage>
<pub-id pub-id-type="doi">10.1186/s13054-016-1579-8</pub-id>
<pub-id pub-id-type="pmid">28010729</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cappi</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Noritomi</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>IT</given-names>
</name>
<name>
<surname>Curi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Loureiro</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Soriano</surname>
<given-names>FG</given-names>
</name>
</person-group>
<article-title>Dyslipidemia: a prospective controlled randomized trial of intensive glycemic control in sepsis</article-title>
<source/>Intensive Care Med
          <year>2012</year>
<volume>38</volume>
<issue>4</issue>
<fpage>634</fpage>
<lpage>641</lpage>
<pub-id pub-id-type="doi">10.1007/s00134-011-2458-z</pub-id>
<pub-id pub-id-type="pmid">22297666</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phetteplace</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Sedkova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>KI</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>NO</given-names>
</name>
<name>
<surname>Lanza-Jacoby</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title><italic>Escherichia coli</italic> sepsis increases hepatic apolipoprotein B secretion by inhibiting degradation</article-title>
<source/>Lipids
          <year>2000</year>
<volume>35</volume>
<issue>10</issue>
<fpage>1079</fpage>
<lpage>1085</lpage>
<pub-id pub-id-type="doi">10.1007/s11745-000-0622-y</pub-id>
<pub-id pub-id-type="pmid">11104013</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vreugdenhil</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Snoek</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Van’t Veer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Greve</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Buurman</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction</article-title>
<source/>J Clin Investig
          <year>2001</year>
<volume>107</volume>
<issue>2</issue>
<fpage>225</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1172/JCI10832</pub-id>
<pub-id pub-id-type="pmid">11160139</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JGH</given-names>
</name>
<name>
<surname>Genga</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Pisitsak</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>AKK</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Survival benefit of a low ratio of visceral to subcutaneous adipose tissue depends on LDL clearance versus production in sepsis</article-title>
<source/>Crit Care
          <year>2018</year>
<volume>22</volume>
<issue>1</issue>
<fpage>58</fpage>
<pub-id pub-id-type="doi">10.1186/s13054-018-1985-1</pub-id>
<pub-id pub-id-type="pmid">29510719</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delgado-Rodriguez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Medina-Cuadros</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martinez-Gallego</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sillero-Arenas</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Total cholesterol, HDL-cholesterol, and risk of nosocomial infection: a prospective study in surgical patients</article-title>
<source/>Infect Control Hosp Epidemiol
          <year>1997</year>
<volume>18</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.2307/30141957</pub-id>
<pub-id pub-id-type="pmid">9013240</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>iTRAQ-based proteomic analysis reveals protein profile in plasma from children with autism</article-title>
<source/>Proteom Clin Appl
          <year>2018</year>
<volume>12</volume>
<issue>3</issue>
<fpage>e1700085</fpage>
<pub-id pub-id-type="doi">10.1002/prca.201700085</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>